Back to results
US 2024/0285734 A1Published application
Gne as a therapeutic agent
OwnerDaniel Darvishinventor
Life of this patent
Estimating the term…
Abstract
The invention relates to composition and methods for expressing UDP-GlcNAc 2-Epimerase/ManNAc Kinase enzyme (GNE) in a living organism. In preferred embodiments, the invention relates to treating disease condition that involves use of therapeutically effective amount of a composition described herein.
Claims20
A method of treating a subject, the method comprising:
- administering to the subject a pharmaceutical composition comprising a recombinant vector comprising a DNA molecule encoding GNE or a therapeutic fragment thereof,
- wherein the recombinant vector has a capsid comprising amino acid residues corresponding to Asp-271, Asn-272, Tyr-446, Asn-470, and Trp-503, as described in SEQ ID NO:
- 19 as Asp-1, Asn-2, Tyr-176, Asn-200, and Trp-233, thereby directing entry of the AAV vector into cells of the subject without a need for sialic on the cells.
A pharmaceutical composition comprising:
- a recombinant vector comprising a DNA molecule encoding GNE or a therapeutic fragment thereof,
- wherein the recombinant vector has a capsid comprising amino acid residues corresponding to Asp-271, Asn-272, Tyr-446, Asn-470, and Trp-503, as described in SEQ ID NO:
- 19 as Asp-1, Asn-2, Tyr-176, Asn-200, and Trp-233, thereby directing entry of the AAV vector into cells of the subject without a need for sialic on the cells.
A pharmaceutical composition comprising:
- a DNA molecule encoding GNE or a therapeutic fragment thereof, and containing at least one mutation or variation within an allosteric domain of GNE,
- wherein the pharmaceutical composition comprises:
- (i) a net negative charge, (ii) an eukaryotic enhancer, and (iii) a pharmaceutically-acceptable carrier, adjuvant, or vehicle.
Dependencies are inferred from the claim text.